Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot

Journal of Investigative Medicine

Volumn 59, Issue 8, 2011, Pages 1233-1238

  El Mesallamy, Hala O ^a   Hamdy, Nadia M ^a   Ezzat, Omnia A ^b   Reda, Ahmed M ^b  

^a Ain Shams University   (Egypt)

^b Egyptian Russian University   (Egypt)

Author keywords

ADMA; AGEs; Diabetic foot associated with neuropathy; Fructosamine; NO; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; FRUCTOSAMINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE DURATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

EID: 84856726557     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0b013e318231db64     Document Type: Article

References (44)

1. Wong MC, Chung JW,Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ. 2007;335:387.
2. Mekkes JR, Loots MAM, VanDerWal AC, et al. Causes, investigation and treatment of leg ulceration. Br J Dermatol. 2003;148:388-401. (Pubitemid 36461316)
3. Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev. 2007;1. 4.
4. Sanchez-Ramirez GM, Caram-Salas NL, Rocha-Gonzalez HI. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. 2006;13:530(1-2), 48-53. (Pubitemid 43037123)
5. Yokoi M, Yamagishi S, Takeuchi M, et al. Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation. Br J Ophthalmol. 2007;91:397-405.
6. American Diabetes Association. Standards of Medical Care in Diabetes. Prevention and Management of Diabetes Complications, Neuropathy screening and treatment Diabetes Care 2011; S27.
7. El-Mesallamy HO, Hammad LN, El-Mamoun TA, et al. Role of advanced glycation end product receptors in the pathogenesis of diabetic retinopathy. J Diabetes Complications. 2011;25:168-174.
8. Nessar A. Advanced glycation endproducts-role in pathology of diabetic complications. Diabetes Res Clin Pract. 2005;67:3-21.
9. Humpert PM, Djuric Z, Kopf S, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol. 2007;7(6):9-14.
10. Hudson BI, Harja E, Moser B, et al. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol. 2005;25(5):879-882. (Pubitemid 40637200)
11. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem. 2006;13(17):1971-1978.
12. De Gennaro CV, Bianchi M, Pascale V, et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit. 2009;15(4):91-101.
13. Wagner FW. Supplement: algorithms of foot care. In: Levin ME, O'Neal LW, eds. The Diabetic Foot. 3rd ed. St. Louis, MO: CV. Mosby; 1983:291-302.
14. Bellizini MC, Dietz WH. Workshop on childhood obesity: summary of the discussion. Am J Clin Nutr. 1999;70(suppl):173S-175S. (Pubitemid 29461136)
15. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158-161.
16. Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973;19:1350-1356.
17. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583-595.
18. Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. Advan Lipid Res. 1968;6:1-68.
19. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982;126(1):131-138. (Pubitemid 13203451)
20. Baker J R, Roger N, Johnson PA. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta. 1983;127(1):87-95. (Pubitemid 13168108)
21. Abraham EC, Huff TA, Cope ND, et al. Determination of the glycosylated hemoglobins (HbA1) with a new microcolumn procedure. Suitability of the technique for assessing the clinical management of diabetes mellitus. Diabetes. 1978;27:931-937. (Pubitemid 9023050)
22. Braunwald E, Fauci AS, Kasper DL. Harrison Principles of Internal Medicine. 15th ed. New York, NY: McGraw- Hill; 2001.
23. Vinik AI. Diabetic neuropathies. Med Clin North Am. 2004;88(4): 947-999. (Pubitemid 39090347)
24. Eckman AS. Diabetic Neuropathy (Nerve Damage) and Diabetes. American Diabetes Association (ADA): 2010. Additional Specific Types of Diabetic Neuropathy. National Diabetes Education Program: Prevention and Early Intervention for Diabetes Foot Problems.
25. Yonem A, Duran C, Unal M, et al. Plasma apelin and asymmetric dimethylarginine levels in type 2 diabetic patients with diabetic retinopathy. Diabetes Res Clin Pract. 2009;84:219-223.
26. Casper GS, Coen DAS. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143-159.
27. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143-159. (Pubitemid 41117297)
28. Pereira EC, Ferderbar S, Bertolami MC, et al. Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin Biochem. 2008;41:1454-1460.
29. Williams SB, Cusco JA, Roddy MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574. (Pubitemid 26081917)
30. Veves A, Akbari CM, Primavera J. Endothelial dysfunction and the expression of endothelial nitric oxide synthase in diabetic neuropathy, vascular disease and foot ulceration. Diabetes. 1998;47:457-463. (Pubitemid 28104210)
31. Palmer RM, Rees DD, Ashton DS, et al. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium dependent relaxation. Biochem Biophys Res Commun. 1988;153:1251-1256.
32. Koc F, Tokac M, Erdem S, et al. Serum asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci Monit. 2010;16(11): CR536-CR539.
33. Vallejo S, Angulo J, Peiro C, et al. Highly glycated oxyhemoglobin impairs nitric oxide relaxations in human mesenteric microvessels. Diabetologia. 2000;43:83-90. (Pubitemid 30129306)
34. Feldman EC, Nelson RW. Canine Diabetes Mellitus. In Canine and Feline Endocrinology and Reproduction. 3rd ed. St. Louis, MO: Saunders; 2004:510.
35. Wautier MP, Boulanger E, Guillausseau PJ, et al. AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thromb Haemost. 2004;91:879-885. (Pubitemid 38647490)
36. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. J Transl Med. 2009;17:7-17.
37. Diego G, Colomba F, Enzo E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23(9):1725-1729.
38. Funabiki K, Tomino Y. Increased serum endogenous secretory receptor for advanced glycation endproduct (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81:196-201.
39. Maillard-Lefebvre H, Boulanger E, Daroux M, et al. Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology. 2009;48:1190-1196.
40. Thornalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37-57.
41. Lukic IK, Humpert PM, Nawroth PP, et al. The RAGE pathway. Ann N Y Acad Sci. 2008;1126:76-80.
42. Goh S-Y, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93(4):1143-1152. (Pubitemid 351519698)
43. Grossin N, Wautier MP, Measb T. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008;34:392-395.
44. Gohda T, Tanimoto M, Moon J-Y, et al. Increased serum endogenous secretory receptor for advanced glycation endproduct (esRAGE) levels in type 2 diabetic patients with decreased renal function. Diabetes Res Clin Pract. 2008;81:196-201.